Ever­est Med­i­cines reach­es its first peak in Chi­na with Trodelvy nod; Cy­cle­ri­on touts da­ta in small study

While strug­gling at home to prove sig­nif­i­cant dif­fer­ence in over­all sur­vival com­pared to stan­dard of care, Gilead’s Trodelvy is head­ed to Chi­na through part­ner Ever­est Med­i­cines.

The coun­try has ap­proved the drug for adult pa­tients with un­re­sectable lo­cal­ly ad­vanced or metasta­t­ic triple-neg­a­tive breast can­cer. Pa­tients must have tak­en two or more pri­or sys­temic ther­a­pies. CEO Ker­ry Blan­chard called the ap­proval a “sig­nif­i­cant mile­stone” for Ever­est as it marks the biotech’s first nod in its home coun­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER